Fisher Asset Management LLC Acquires New Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Fisher Asset Management LLC acquired a new stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 62,372 shares of the company’s stock, valued at approximately $1,006,000. Fisher Asset Management LLC owned 0.08% of Deciphera Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its holdings in Deciphera Pharmaceuticals by 96.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after purchasing an additional 997 shares during the period. Exchange Traded Concepts LLC raised its holdings in Deciphera Pharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,447 shares of the company’s stock worth $169,000 after purchasing an additional 2,649 shares during the period. Aigen Investment Management LP acquired a new stake in Deciphera Pharmaceuticals in the third quarter worth $181,000. Diversified Trust Co acquired a new stake in Deciphera Pharmaceuticals in the fourth quarter worth $193,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Deciphera Pharmaceuticals by 20.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,178 shares of the company’s stock worth $196,000 after purchasing an additional 2,102 shares during the period. 70.96% of the stock is currently owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Stock Performance

NASDAQ:DCPH opened at $25.37 on Friday. The stock has a market capitalization of $2.09 billion, a PE ratio of -11.08 and a beta of 0.20. Deciphera Pharmaceuticals, Inc. has a 1-year low of $9.90 and a 1-year high of $25.47. The firm has a fifty day simple moving average of $17.25 and a 200 day simple moving average of $15.21.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings data on Tuesday, February 6th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. The company had revenue of $48.30 million for the quarter, compared to analyst estimates of $45.93 million. During the same period in the previous year, the business earned ($0.60) EPS. Deciphera Pharmaceuticals’s revenue for the quarter was up 32.9% compared to the same quarter last year. On average, equities analysts predict that Deciphera Pharmaceuticals, Inc. will post -2.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Stifel Nicolaus increased their target price on shares of Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. JPMorgan Chase & Co. lifted their price target on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Wednesday, March 20th. Leerink Partnrs downgraded Deciphera Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, April 29th. JMP Securities restated a “market perform” rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday, April 30th. Finally, Jonestrading reaffirmed a “hold” rating and set a $25.60 price target on shares of Deciphera Pharmaceuticals in a research note on Monday, April 29th. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $24.17.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.